secwatch.observer — SEC 8-K summary
======================================

Issuer:     CG Oncology, Inc. (CGON)
CIK:        0001991792
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-069825
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CG Oncology Q1 net loss $34.5M; BLA submission on track for H2 2025
-------------------------------------------------------------------

- Net loss of $34.5M ($0.45/share) vs $16.9M ($0.36) a year ago; R&D spend rose to $27.5M.
- Cash $688.4M as of March 31, 2025; expected to fund operations into first half of 2028.
- BOND-003 Cohort C: 75.5% CR at any time; 24-month CR rate 42.3% by K-M; 97.3% progression-free at 24 months.
- Cohort P: 90.5% high-grade recurrence-free survival at 3 and 9 months in BCG-unresponsive Ta/T1 disease.
- Anticipates starting BLA submission for cretostimogene in HR BCG-unresponsive NMIBC in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1991792/000095017025069825/0000950170-25-069825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1991792/000095017025069825/ck0001991792-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer